The vaccine has been tested on 14 patients, researchers at John Hopkins University, Baltimore, Maryland, USA, reported.
It uses laboratory-cultured cancer cells that have been genetically modified to include the GM-CSF gene to boost the immune system.
Patients were given the vaccine after having surgery to remove the tumor, and 12 also underwent radiotherapy and chemotherapy. Six of the patients had an additional course of monthly vaccinations over a period of 3 months.
The researchers found that parts of the immune system were activated in 3 cases where patients had received the highest doses.
Side-effects from the treatment were limited to skin reactions and itchiness following vaccination.
Researcher Dr Elizabeth Jaffee said: "This study was just a first step, but we are encouraged to find that it is safe, and initiates an immune response in certain doses."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com